SFZN Stock Analysis: Siegfried Holding | SW
Drug Manufacturers - Specialty & Generic | SW, Switzerland | Market Cap: 2.957m CHF | 12M Return: -14% | CH0014284498 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.15M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Siegfried Holding AG (SFZN) is a Swiss pharmaceutical company that operates as a contract development and manufacturing organization (CDMO) for active pharmaceutical ingredients (APIs) and finished dosage forms, serving customers worldwide. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Siegfrieds operations are divided into two main segments: drug substances and drug products. The drug substances segment includes exclusive synthesis of custom APIs alongside a portfolio of non-exclusive APIs and pharma-grade substances, with therapeutic focus areas spanning anesthetics, pain and addiction treatment, central nervous system disorders, respiratory diseases, and caffeine for human health and nutrition. The drug products segment covers steriles (fill and finish in vials, ampoules, cartridges, and pre-filled syringes), ophthalmics, inhalation products, oral solid dosage forms, and viral vectors for gene therapy applications.
In addition to its core manufacturing services, Siegfried provides supporting technologies including chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapy capabilities. The CDMO business model serves pharmaceutical and biotechnology clients seeking outsourced development and production, allowing Siegfried to generate revenue through long-term contracts, milestone payments, and manufacturing volumes rather than direct drug commercialization.
- API synthesis revenue grows on CDMO outsourcing demand
- Sterile fill-finish margins expand with capacity utilization gains
- Cell and gene therapy investments shape long-term capital allocation
| Net Income: 171.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 0.47 > 1.0 |
| NWC/Revenue: 64.57% < 20% (prev 47.78%; Δ 16.79% < -1%) |
| CFO/TA 0.07 > 3% & CFO 165.8m > Net Income 171.3m |
| Net Debt (820.0m) to EBITDA (313.2m): 2.62 < 3 |
| Current Ratio: 3.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (43.9m) vs 12m ago 2.02% < -2% |
| Gross Margin: 26.97% > 18% (prev 25.69%; Δ 1.27% > 0.5%) |
| Asset Turnover: 61.12% > 50% (prev 65.64%; Δ -4.51% > 0%) |
| Interest Coverage Ratio: 19.38 > 6 (EBIT TTM 210.9m / Interest Expense TTM 10.9m) |
| A: 0.36 (Total Current Assets 1.22b - Total Current Liabilities 353.1m) / Total Assets 2.42b |
| B: 0.44 (Retained Earnings 1.06b / Total Assets 2.42b) |
| C: 0.10 (EBIT TTM 210.9m / Avg Total Assets 2.19b) |
| D: 0.70 (Book Value of Equity 994.7m / Total Liabilities 1.42b) |
| Altman-Z'' = 5.16 = AAA |
| DSRI: 1.00 (Receivables 328.0m/317.0m, Revenue 1.34b/1.29b) |
| GMI: 0.95 (GM 25.69% / 26.97%) |
| AQI: 1.05 (AQ_t 0.05 / AQ_t-1 0.04) |
| SGI: 1.04 (Revenue 1.34b / 1.29b) |
| TATA: 0.00 (NI 171.3m - CFO 165.8m) / TA 2.42b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of October 14, 2026, the stock is trading at CHF 68.35 with a total of 105,265 shares traded. Over the past week, the price has changed by -2.84%, over one month by -6.56%, over three months by -6.31% and over the past year by -14.02%.
Current recommended Stop Loss: 65.80 (which is 3.7% or 1.3 ATR below the current price).
Siegfried Holding has no consensus analysts rating.
P/E Trailing = 17.2634
P/E Forward = 14.881
P/S = 2.2046
P/B = 3.2768
P/EG = 1.3907
Revenue TTM = 1.34b CHF
EBIT TTM = 210.9m CHF
EBITDA TTM = 313.2m CHF
Long Term Debt = 375.2m CHF (from longTermDebt, last fiscal year)
Short Term Debt = 200.0m CHF (from shortTermDebt, last fiscal year)
Debt = 925.2m CHF (from shortLongTermDebtTotal, last quarter)
Net Debt = 820.0m CHF (calculated: Debt 925.2m - CCE 105.2m)
Enterprise Value = 3.78b CHF (2.96b + Debt 925.2m - CCE 105.2m)
Interest Coverage Ratio = 19.38 (Ebit TTM 210.9m / Interest Expense TTM 10.9m)
EV/FCF = -207.1x (Enterprise Value 3.78b / FCF TTM -18.2m)
FCF Yield = -0.48% (FCF TTM -18.2m / Enterprise Value 3.78b)
FCF Margin = -1.36% (FCF TTM -18.2m / Revenue TTM 1.34b)
Net Margin = 12.77% (Net Income TTM 171.3m / Revenue TTM 1.34b)
Gross Margin = 26.97% ((Revenue TTM 1.34b - Cost of Revenue TTM 979.6m) / Revenue TTM)
Gross Margin QoQ = 26.97% (prev 26.97%)
Tobins Q-Ratio = 1.56 (Enterprise Value 3.78b / Total Assets 2.42b)
Interest Expense / Debt = 1.18% (Interest Expense 10.9m / Debt 925.2m)
Taxrate = 19.29% (40.9m / 211.8m)
NOPAT = 170.2m (EBIT 210.9m * (1 - 19.29%))
Current Ratio = 3.45 (Total Current Assets 1.22b / Total Current Liabilities 353.1m)
Debt / Equity = 0.93 (Debt 925.2m / totalStockholderEquity, last quarter 994.7m)
Debt / EBITDA = 2.62 (Net Debt 820.0m / EBITDA 313.2m)
Debt / FCF = -44.96 (negative FCF - burning cash) (Net Debt 820.0m / FCF TTM -18.2m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.81% (Net Income 171.3m / Total Assets 2.42b)
RoE = 16.61% (Net Income TTM 171.3m / Total Stockholder Equity 1.03b)
RoCE = 14.99% (EBIT 210.9m / Capital Employed (Equity 1.03b + L.T.Debt 375.2m))
RoIC = 7.75% (NOPAT 170.2m / Invested Capital 2.20b)
WACC = 6.17% (E(2.96b)/V(3.88b) * Re(7.80%) + D(925.2m)/V(3.88b) * Rd(1.18%) * (1-Tc(0.19)))
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 7.92 | Cagr: 0.47%
[DCF] Fair Price = unknown (Cash Flow -18.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 95.96 | Revenue CAGR: 2.12% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=4.15 | Chg30d=+0.58% | Revisions=-22% | GrowthEPS=+12.5% | GrowthRev=+7.2%
EPS next Year (2027-12-31): EPS=4.73 | Chg30d=+1.46% | Revisions=-22% | GrowthEPS=+14.0% | GrowthRev=+10.0%
[Analyst] Revisions Ratio: -27% (up=4, down=8)